U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H21N3O2S.C4H6O4
Molecular Weight 413.488
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUMATRIPTAN SUCCINATE

SMILES

OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1

InChI

InChIKey=PORMUFZNYQJOEI-UHFFFAOYSA-N
InChI=1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H21N3O2S
Molecular Weight 295.4
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist indicated for acute treatment of migraine with or without aura in adults. Sumatriptan is structurally similar to serotonin (5-HT), and is a 5-HT receptor (types 5-HT1D and 5-HT1B) agonist. The specific receptor subtypes it activates are present on the cranial arteries and veins. Acting as an agonist at these receptors, sumatriptan reduces the vascular inflammation associated with migraines. The specific receptor subtype it activates is present in the cranial and basilar arteries. Activation of these receptors causes vasoconstriction of those dilated arteries. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan is effective for ending or relieving the intensity of migraine and cluster headaches. It is most effective taken early after the start of the pain. Injected sumatriptan is more effective than other formulations. Large doses of sumatriptan can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to greenish-black, due to the integration of sulfur into the hemoglobin molecule. Serious cardiac events, including some that have been fatal, have occurred following the use of sumatriptan injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation (V-Fib).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
330.0 nM [IC50]
38.3 nM [EC50]
35.0 nM [EC50]
5.3 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
IMITREX

Approved Use

Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1)

Launch Date

1997
Primary
IMITREX

Approved Use

Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1)

Launch Date

1997
Primary
IMITREX

Approved Use

Sumatriptan Injection, USP is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with Sumatriptan Injection, USP, reconsider the diagnosis before Sumatriptan Injection, USP is administered to treat any subsequent attacks. Sumatriptan Injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan Injection, USP is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults (1) Acute treatment of cluster headache in adults (1) Limitations of Use: Use only if a clear diagnosis of migraine or cluster headache has been established (1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks (1)

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
42 ng/mL
3 mg single, subcutaneous
dose: 3 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
77 ng/mL
3 mg single, intravenous
dose: 3 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
49 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
90 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
112 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
144 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
29 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
80 ng/mL
8 mg single, subcutaneous
dose: 8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 ng/mL
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
194 ng/mL
16 mg single, subcutaneous
dose: 16 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
41 ng × h/mL
3 mg single, subcutaneous
dose: 3 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
43 ng × h/mL
3 mg single, intravenous
dose: 3 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
158 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
380 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
44 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
476 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
590 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
83 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
105 ng × h/mL
8 mg single, subcutaneous
dose: 8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14 ng × h/mL
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
239 ng × h/mL
16 mg single, subcutaneous
dose: 16 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.6 h
3 mg single, subcutaneous
dose: 3 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.6 h
3 mg single, intravenous
dose: 3 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.1 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.5 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.4 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
83 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.5 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
8 mg single, subcutaneous
dose: 8 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
1 mg single, subcutaneous
dose: 1 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.1 h
16 mg single, subcutaneous
dose: 16 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
SUMATRIPTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / month multiple, oral
Dose: 200 mg, 1 times / month
Route: oral
Route: multiple
Dose: 200 mg, 1 times / month
Sources:
unhealthy, 18 - 65 years
n = 94
Health Status: unhealthy
Condition: acute migraine with aura
Age Group: 18 - 65 years
Sex: M+F
Population Size: 94
Sources:
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
(SUMATRIPTAN)
12 mg subcutaneous injections
Sources:
unhealthy, 35 years
n = 1
Health Status: unhealthy
Condition: migraine
Age Group: 35 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Ischemic colitis...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Sources:
6 mg 2 times / day multiple, subcutaneous
Overdose
Dose: 6 mg, 2 times / day
Route: subcutaneous
Route: multiple
Dose: 6 mg, 2 times / day
Sources:
unhealthy, 36 years
n = 1
Health Status: unhealthy
Condition: episodic cluster headache
Age Group: 36 years
Sex: M
Population Size: 1
Sources:
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Other AEs: Abnormal physical sensation, Abnormal physical sensation...
Other AEs:
Abnormal physical sensation (6%)
Abnormal physical sensation (6%)
Abnormal physical sensation (6%)
Sensation of pressure (8%)
Chest tightness of (2%)
Throat tightness (3%)
Pain (1%)
Pressure (3%)
Vertigo (2%)
Malaise and fatigue (3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Ischemic colitis 1 patient
Disc. AE
300 mg single, oral
Overdose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Co-administed with::
(SUMATRIPTAN)
12 mg subcutaneous injections
Sources:
unhealthy, 35 years
n = 1
Health Status: unhealthy
Condition: migraine
Age Group: 35 years
Sex: F
Population Size: 1
Sources:
Pain 1%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Chest tightness of 2%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Vertigo 2%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Malaise and fatigue 3%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Pressure 3%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Throat tightness 3%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Abnormal physical sensation 6%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Abnormal physical sensation 6%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Abnormal physical sensation 6%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Sensation of pressure 8%
100 mg single, oral
Highest studied dose
unhealthy, adult
n = 437
Health Status: unhealthy
Condition: migraine with or without aura
Age Group: adult
Sex: unknown
Population Size: 437
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
yes [IC50 6.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
weak (co-administration study)
Comment: coadministered with clarithromycin: mean sumatriptan AUC(infinity) and Cmax values after administration of combination treatment were 9% and 14% higher, respectively
yes
PubMed

PubMed

TitleDatePubMed
Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group.
1998 Nov-Dec
Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
1999 Aug
Fatal cardiac arrhythmia after oral sumatriptan.
1999 Jul-Aug
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
2000 Feb
Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry.
2000 Nov
2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study.
2000 Nov-Dec
Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.
2001
Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
2001
Managing migraine: strategies for successful patient outcomes.
2001 Apr
Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine.
2001 Apr
Cluster headache: review of the literature.
2001 Apr
[Current topics: expectation for new triptans].
2001 Apr 10
[Migraine: selection of therapeutic agents to be applied during its attack].
2001 Apr 10
[Aspirin, triptan tablet, nasal spray, injection. Even the most severe migraine capitulates].
2001 Apr 19
A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients.
2001 Aug
Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis.
2001 Feb
Economic implications of early treatment of migraine with sumatriptan tablets.
2001 Feb
Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets.
2001 Feb
Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine.
2001 Feb
A systematic review of the use of triptans in acute migraine.
2001 Feb
Butterscotch masks the bitter taste of sumatriptan nasal spray.
2001 Feb
Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan.
2001 Jan
Effect of sumatriptan on health care resource use among patients with migraine.
2001 Jan
pH-mediated field-amplified sample stacking of pharmaceutical cations in high-ionic strength samples.
2001 Jan
Unravelling the pharmacological profile of the canine external carotid vasodilator '5-HT1-like' receptors: coexistence of sympatho-inhibitory 5-HT1B and postjunctional 5-HT7 receptors.
2001 Jan
Interictal and postictal contingent negative variation in migraine without aura.
2001 Jan
[First manifestation of migraine as acute confusional state: "confusional migraine" and diagnostic problems].
2001 Jan-Feb
Effect of rizatriptan in the spectrum of headache.
2001 Jun
Recent development in paediatric headache.
2001 Jun
Headache and female hormones: what you need to know.
2001 Jun
Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons.
2001 Jun
Complicated migraine and migraine variants.
2001 Mar
Status migrainosus in children and adolescents.
2001 Mar
Sumatriptin vs dihydroergotamine: patient preference.
2001 Mar
Zolmitriptan versus sumatriptan comparison trial.
2001 Mar
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.
2001 Mar
Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphé nuclei.
2001 Mar
Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs.
2001 Mar
The GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction: resemblance to the 5-HT(1B), but not to the 5-HT(1D) or 5-ht(1F), receptor subtype.
2001 Mar
Evidence for 5-HT(1B/1D) and 5-HT(2A) receptors mediating constriction of the canine internal carotid circulation.
2001 Mar
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis.
2001 May
Oral almotriptan in the treatment of migraine: safety and tolerability.
2001 May
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model.
2001 May 1
Patents

Sample Use Guides

Migraine Headache. Oral: 25 mg, 50 mg, or 100 mg PO (taken with fluids); Not to exceed 100 mg/dose; additional doses q2hr PRN. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hr; Not to exceed 12 mg SC q24hr Cluster Headache. Subcutaneous Injection: 6 mg (0.5 mL) SC with autoinjector; may repeat in ≥1 hour; Not to exceed 12 mg SC q24hr
Route of Administration: Other
The uptake of sumatriptan and other triptans via OCT1 and OCT3 was characterized using HEK293 cells stably transfected to overexpress wild-type OCT1 or OCT3. For measuring the uptake in human hepatocytes, was used cryopreserved human hepatocytes (Gibco Life Technologies, Darmstadt, Germany) obtained from a single donor with two fully active OCT1 alleles. Triptan uptake in OCT1 and OCT3-overexpressing HEK293 cells was measured by incubating the cells with varying concentrations of the substrates in 12-well plates for two minutes at pH 7.4 and 378C. The reaction was stopped with ice-cold buffer, the cells were lysed with 80% acetonitrile, and the intracellularly accumulated triptans were quantified by liquid chromatography coupled to tandem massspectrometry.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:12:39 GMT 2023
Edited
by admin
on Fri Dec 15 15:12:39 GMT 2023
Record UNII
J8BDZ68989
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUMATRIPTAN SUCCINATE
EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TREXIMET COMPONENT SUMATRIPTAN SUCCINATE
Common Name English
SUMATRIPTAN SUCCINATE [USP-RS]
Common Name English
ZEMBRACE SYMTOUCH
Brand Name English
Sumatriptan succinate [WHO-DD]
Common Name English
SUMATRIPTAN SUCCINATE [MART.]
Common Name English
SUMATRIPTAN SUCCINATE [USAN]
Common Name English
ONZETRA XSAIL
Brand Name English
SUMATRIPTAN SUCCINATE [USP MONOGRAPH]
Common Name English
TREXIMET
Common Name English
SUMATRIPTAN SUCCINATE [EP MONOGRAPH]
Common Name English
SUMATRIPTAN SUCCINATE [JAN]
Common Name English
SUMATRIPTAN SUCCINATE [VANDF]
Common Name English
SUMATRIPTAN SUCCINATE [ORANGE BOOK]
Common Name English
SUMATRIPTAN GALPHARM
Brand Name English
NSC-760362
Code English
1H-INDOLE-5-METHANESULFONAMIDE, 3-(2-(DIMETHYLAMINO)ETHYL)-N-METHYL-, BUTANEDIOATE (1:1)
Systematic Name English
GR-43175C
Code English
SUMATRIPTAN SUCCINATE [MI]
Common Name English
SUMATRIPTAN SUCCINATE COMPONENT OF TREXIMET
Common Name English
GR 43175C
Code English
SUMATRIPTAN (AS SUCCINATE)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
EMA ASSESSMENT REPORTS SUMATRIPTAN GALPHARM (REFUSED: MIGRAINE DISORDERS)
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT001003
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
RXCUI
67158
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY RxNorm
PUBCHEM
59772
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
EPA CompTox
DTXSID60145966
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
EVMPD
SUB15437MIG
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
SMS_ID
100000077527
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
RS_ITEM_NUM
1642201
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
USAN
AA-44
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
FDA UNII
J8BDZ68989
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
DAILYMED
J8BDZ68989
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
NCI_THESAURUS
C29470
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
CAS
103628-48-4
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
MERCK INDEX
m10396
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY Merck Index
CHEBI
64359
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
NSC
760362
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
ChEMBL
CHEMBL128
Created by admin on Fri Dec 15 15:12:39 GMT 2023 , Edited by admin on Fri Dec 15 15:12:39 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Calculate the percentage of sumatriptan related compound A free base in the portion of sumatriptan free base taken
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY